|Description||Antibodies to gangliosides are associated with a number of demyelinating neurological diseases including Guillain-Barre syndrome, Chronic demyelinating polyneuropathy and Multifocal motor neuropathy. Also referred to as anti-glycolipid antibodies.|
|Indication||GBS, multifocal motor neuropathies, motor neurone disease, CIDP, Miller-Fisher syndrome.
|Additional Info||The antibody screen performed by Glasgow includes the detection of IgG and IgM to anti-GM1, GM2, GD1a, GD1b and GQ1b antibodies. If any of these are positive a more extensive panel of tests is performed with end-point dilution analysis.|
|Collection Conditions||No restrictions|
|Ref. Range (Male)||negative/positive|
|Ref. Range (Female)|| |
|Ref. Range (Paed)|| |
|Ref. Range Notes||Interpretice result|
|Units|| - Not Defined -|
|IP Acute TAT||- Contact Laboratory|
|IP Routine TAT||28 days|
|GP Acute TAT||- Contact Laboratory|
|GP Routine TAT||28 days|
Originally edited by : BD. Review due on 14/09/2018 14:18:15. Published By AM on 14/09/2017 14:18:15.